Nanogen adds EBV-detecting real-time probes and primers to portfolio

By Lisa Kerner

Erie, Pa., April 25 - Nanogen, Inc.'s expanded molecular reagent product portfolio now includes real-time probes and primers designed to detect the presence of Epstein-Barr virus (EBV), which causes infectious mononucleosis and underlies other lymphoproliferative disorders such as Burkitt's lymphoma.

The company said its MGB Alert EBV analyte-specific reagent can be used to develop and validate assays to detect sequences within the putative membrane antigen p140 region of the viral BNRF1 gene.

Particularly at risk for EBV-associated lymphoproliferation are people undergoing stem cell or solid organ transplantation. Lymphoproliferation may lead to post-transplant lymphoproliferative disorder; an infectious-mono like illness that can mimic transplant rejection.

"The EBV reagent is the newest addition to our growing menu of MGB Alert products, which includes [analyte-specific reagents] designed to detect sequences associated with herpes simplex viruses 1 and 2, cytomegalovirus, enterovirus, Chlamydia pneumoniae, Mycoplasma pneumoniae, and norovirus 1 and 2, among others," chairman and chief executive officer Howard Birndorf said in a company news release.

Nanogen, based in San Diego, develops diagnostic products and technologies for use by researchers, clinicians and physicians.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.